Summary This latest Pharmaceutical and Healthcare disease pipeline guide Crohn’s Disease - Pipeline Review, H1 2020, provides an overview of the Crohn’s Disease (Gastrointestinal) pipeline landscape.
Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.
Report Highlights This Pharmaceutical and Healthcare latest pipeline guide Crohn’s Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Crohn’s Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Crohn’s Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 36, 30, 1, 70, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Crohn’s Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Crohn’s Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Crohn’s Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Gastrointestinal)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Posterior Uveitis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Posterior Uveitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Posterior Uveitis Clinical trials scenario.This report provides top line data relating to the clinical trials...
Behcet Disease Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Behcet Disease Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Behcet Disease Clinical trials scenario.This report provides top line data relating to the clinical trials on...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, and Mylan N.V. The global arthritis monoclonal antibodies market is expected to decline from $46.48 billion in 2019 to $45.18 billion in 2020 at a compound annual growth...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.